International Journal of Early Childhood Special Education (INT-JECS)
ISSN: 1308-5581 Vol 14, Issue 04 2022

A CASE REPORT ON CEREBRAL VENOUS SINUS THROMBOSIS

Ritu Shende[1], Dharti Meshram[2], Indu Alwadkar[3], Ashish Bhagat[4], Pratiksha Munjewar[5]

1] GNM 2nd year, Florence Nightingale Training College of Nursing. Sawangi (M) Wardha India, Email: ritushende2001@gmail.com
2] Nursing Tutor, Florence Nightingale Training College of Nursing, Sawangi (M) Wardha, Email: dhartimeshram9@gmail.com, 7507517801
3] Principal of Florence Nightingale Training College of Nursing,Sawangi (M) Wardha, Email: indu.alwadkar@gmail.com, 9960278995
4] Research Consultant, Department of Research and Development, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Wardha, Email: bhagat.ashish.18@gmail.com
5] Department of Medical-Surgical Nursing, Smt. Radhikabai Meghe Memorial College of Nursing, Datta Meghe Institute of Medical Sciences, Sawangi, Wardha, Maharashtra.

Abstract
Background: CVT (Cerebral venous and sinus thrombosis) can cause a range of clinical signs, from a single headache to a deep coma.The scenario is better than before assumed, with prospective trials reporting an independent survival rate of more than 80% of patients.CVT is a difficult illness to diagnose because of the wide range of clinical symptoms and indications. It is frequently unrecognized at the outset. Contraceptive pills are also a significant hazard factor.Medical manifestations range from headache with papilledema, to impairment of focal, and coma.
Presentation of case A 17-year-old male was admitted to Tertiary care Hospital with the chief complaint of, nausea, vomiting, headache, papilledema in the last 5 days or two episodes of seizures, and breathlessness. All necessary investigation was done such as history collection patient had a history of head injury before 7-month, physical examination done, all investigation done such as measured intracranial pressure increased that is 18 mmHg, urgent neuroimaging to use CT to confirm the diagnosis, CT shows the classic "delta sign," the thrombus directly, show impaired venous flow.venography of CT can reveal missing flow in thrombosed veins or sinuses, as well as partimprovement circumferential in sinuses thrombosed venous. A doctor diagnosed cerebral venous sinus thrombosis.The patient received symptomatic treatment such as anticoagulant therapy, and anticonvulsant therapy for the control of seizures. Fibrinolysis, heparin, aspirin, dipyridamole in. Levi, Inj. Pantoprazole, Inj. Optineurin, Inj. Emset, Inj. Mannitol. The severity of the Symptoms was minimized.He suffered from convulsive status and was administered intravenous lorazepam and phenytoin.
Discussion: The patient received the symptomatic treatment and the patient's condition is stable.It isan uncommon condition. According to research, the incidence is between 1.32 and 1.57 per 100 000.Women are more likely than men to suffer from this condition, which is particularly widespread in the younger generation.

-**Keywords**:Fibrinolysis, Thromboembolism, Embolism, Delta sign, Stork, Anticoagulant.

Introduction

CVST in that clot of blood forms in the brain in the venous sinus's region due to this draining from the brain affected, the burden builds up in the blood vessels so due to this pressure rises in the vessels. This might result in brain enlargement or hemorrhage.[1]Due to stroke brain damage and the central nervous system can be affected. That is a network of veins originating among the dura mater layer, the brain's strong outside layer this lies directly beneath the skull. It is a dangerous condition that necessitates immediate medical intervention.[2] This ismore common in females than males. 0.22 to 1.57 per 100,000 is the incidence rate.[3]
Idiopathic and local diseases are the reasons and hazard factors for thrombosis in cerebral venous sinuses such as damage to the brain and skull Mastoiditis and other intracranial and local regional infections Systemic problems Pregnancy or puerperium, estroprogestative, and steroid therapy are all examples of hormonal therapy. Immobilization, surgery, and head injury Connective tissue disease, hematologic and hypercoagulable disorders

DOI: 10.9756/INTJECSE/V14I4.316

Malignancy Infection throughout the body Dehydration[4.] According to the International Study, one of the researchers found that in Cerebral Vein and Dural Sinus Thrombosis, up to 85 percent of adult clients have at least one risk factor, with oral contraception being the most frequent, followed by a prothrombotic disease.[5]Generally, the clinical symptoms are seventy-five percent have a long-term headache, forty-nine percent have papilledema, 34 percent have a deficiency in motor and sensory, Seizures 37%, 30% have drowsiness, mental abnormalities, Coma, confusion,12 percent dysphasia, 12 percent Multiple cranial nerve palsies, 3 percent cerebellar in coordination, 2 percent Nystagmus, 2 percent hearing loss, 3 percent bilateral or alternating cortical signs.[6]It is highly variable and difficult to make a diagnosis It also has a wide range of etiologies and prognoses. There is an association between poverty and education in underdeveloped countries, which is worth noting.[7]The pathophysiological processes of CVT are not entirely known or involve a complicated combination of hemodynamic and brain parenchymal alterations.[8]

The clinical diagnosis of CVT is verified by neuroimaging. A CBC, panel of coagulation, the panel of chemistry, and inflammatory indicators like sedimentation rate or C-reactive protein should be conducted in the laboratory to determine proinflammatory conditions.CT, CVTMRIusing While has greater sensitivity and specificity than CT, diagnostic orassenting venography is essential to rule out cerebral venous thrombosis.MRI is regarded as the gold standard in detecting CVT since it has a better sensitivity than CT.If MRI or MRV diagnosis is still doubted then angiography of intra-arterial is recommended. Angiography permits better visibility of the cerebral veins and aids in the detection of structural variants of normal venous anatomy that mimic CVT.[9]

The first focus of management is on recognizing and treating serious consequences of CVT (thrombosis of cerebral venous), such as ICP (pressure of Intracranial), seizures, or coma. Anticonvulsant with seizures prophylaxis therapy is initiated if the seizures occurred. Because of the possibility of hemorrhagic change of brain infarcts before anticoagulant medication, anticoagulation has been contentious.Although anticoagulant medication improves clinical outcomes for the vast majority of patients,there is a small subset of people who don't, and their medical condition deteriorates disdain anticoagulation.In this case, poor improvement in systematic or catheter-directed thrombolysis is suggested if the anticoagulant treatment not responding.[10]Surgical intervention is required if is there medical treatment not responding that is thrombectomy. along with medical and surgical treatment, supportive care should be mentioned.[11]

Patient information: A 17-year-old male was admitted to Tertiary care Hospital with the chief complaint of nausea, vomiting, headache, papilledema in the last 5 days or two episodes of seizures, and breathlessness. All necessary investigation was done such as history collection patient had a history of head injury before 7-month, physical examination done, all investigation done such as measured intracranial pressure increased that is 18 mmHg, urgent neuroimaging to check the diagnosis, by CT show the classic "delta sign," the thrombus directly, show impaired venous flow. venography in CT displaysabsented movement in thrombosed sinusesor veins and fractional circumferential development of venous sinuses thrombosed. A doctor diagnosed cerebral venous sinus thrombosis.The patient received symptomatic treatment provided to the Patient such as anticoagulant therapy, Seizure controltreatment,and intracranial hypertension management. Fibrinolysisheparin, aspirin, dipyridamole Inj. Levi, Inj. Pantoprazole, Inj. Optineurin, Emset, Inj. Mannitol. He developed convulsive status epilepticus which was treated with intravenous lorazepam and intravenous phenytoin. The severity of the convulsion Symptoms was minimized. He was mentally stable, conscious, and oriented to date, time, and the place had maintained a good relationship with the doctor and nurse and as well as another patient also.

Timeline: He took treatment in tertiary care hospital and he got the proper treatment taking medication and now he has been in good condition.

Data Extraction.

Data extracted from Hand book, PUB MED, Medline, and Cochrane database library.

Discussion:

The patient received symptomatic treatmentsymptoms are minimized but the patient's prognosis was improved.outcomes of VST are good when an exact diagnosis and treatment. according to international studies related to thrombosis of a cerebral vein, approximately 57 percent of the patient had no present symptoms or deficits at a follow-up services time of 16 months. In that 8% of clients died or 2% of a client have deficits.[12]

One of the investigators found that CSVT is a rare type of stroke this primarily affected people in their twenties and thirties. Headache is the most common sign. If other imaging modalities fail, MRI, CTV, MRV, and cerebral angiography are important to use fordiagnosis. The main treatment is LMWH anticoagulation, while endovascular

DOI: 10.9756/INTJECSE/V14I4.316

thrombolysis is still debatable. If cerebral bleeding is used as an anticoagulant, it is not considered a contraindication. CVT patients are at a higher risk of recurrence of CVT.[13]

One of the researchers reveals that the first focus of management is on recognizing and treating life-threatening consequences of CVT (thrombosis in cerebral venous), such as enlarged pressure of intracranial,coma, and convulsion.The focus must then move to a particular treatment, such as anticoagulation, or thrombectomy. who are surviving a long time there is a chance for neurological damage.[14]

some researchers found that COVID infection has been linked to hypercoagulability, as well as an increased risk of thromboembolism in venous, with pulmonary embolism or deep vein thrombosis.Doctorsmust be on the lookout for thromboembolism signs and symptoms those are taking the vaccine of COVID AstraZeneca.[15]

Conclusion:

It is an uncommon serious neurologic disorder.CSVT is a comparatively uncommon disorder that accounts for around 1% of complete strokes.Imaging acting a critical part in the analysis.Because parenchymal in brain changes or venous thrombus development is possibly alterable, quick and adequate remedialtreatment is critical.TOF magnetic resonance imaging venography, contrast-enhanced MR venography, and CT are the mostvaluablemethods for diagnosis of it.Appropriate analysis and action can significantly minimize mortality or morbidity, and significantly improve the result of affected patients.Because of the higher mortality rates, more studies comparing different medications are needed to aid in the treatment of people with CVT.[16]

One of the investigators revealed that 87.5% of women clients have the majority of COVID-19 or CSVT and it is typically informed in young people. in this study, data reveal that age may not be as important in predicting CVST hazards in COVID-19 clients as before assumed.That suggested mortality rate is also low in the current study.[17]

Other researchers found that MRI brain with MRV is complex in diagnosis together through indicators (evidence of thrombus inside the afflicted veins) and indirect signals (parenchymal alterations) of CVST and their follow-up.Following proper medication and care of nursing, twenty-one individuals recovered well.Six clients with hemorrhagic infarction developed persistent localized nervous deficits.One client died, and 12 clients were not followed up on. in this study the 2. 5% fatality rate was attributed to early diagnosis and proper management. Intractable convulsion, unconsciousness, hemorrhagic infarction, and advanced age are all related to a bad prognosis. one of the researchers foundthe majority of patients had a favorable prognosis because of thrombus and vessel recanalization.[18]

Clients with recurrent papilledema or thus elevated intracranial pressure must undergo serial visual field evaluations or be evaluated for Cerebral Spinal Fluid shunting surgery. Early detection of the illness and administration of proper treatment likely reduces morbidity or mortality.[19]Different studies on sinus infections and thrombosis were reviewed[20-25].

Antithrombosis is the first-line treatment for cerebral venous and Dural sinus thrombosis, according to the European Federation of Neurological Societies recommendations.The reason for its usage is to promote natural thrombus resolve and recanalization of the blocked vein or sinus, reduce thrombus circulation, treat primary prothrombotic conditions, and avoid consequences like pulmonary thromboembolism.Action is typically initiated by dose-used to venous heparin ranging from 3000 to 5000 IU or body-weight-adjusted subcutaneous low-molecular-weight heparin till the patient stabilizes.[20]

Consent

The patient and patient's relative were informed and taken written consent from the patient's relative before initiation of the case report.

Competing interests: Nil

References:

1. Dirnagl U, Klehmet J, Braun JS, Harms H, Meisel C, Ziemssen T, Prass K, Meisel A. stroke-induced immunodepression: experimental evidence and clinical relevance. Stroke. 2007 Feb 1;38(2):770-3.
2. Hall ED, Braugher JM. Central nervous system trauma and stroke: II. Physiological and pharmacological evidence for the involvement of oxygen radicals and lipid peroxidation. Free Radical Biology and Medicine. 1989 Jan 1;6(3):303-13.
3. Kamel H, Iadecola C. Brain-immune interactions and ischemic stroke: clinical implications. Archives of neurology. 2012 May 1;69(5):576-81.
4. Ulivi L, Squitieri M, Cohen H, Cowley P, Werring DJ. Cerebral venous thrombosis: a practical guide. Practical neurology. 2020 Oct 1;20(5):356-67.

DOI: 10.9756/INTJECSE/V14I4.316

5. Silvis SM, De Sousa DA, Ferro JM, Coutinho JM. Cerebral venous thrombosis. Nature Reviews Neurology. 2017 Sep;13(9):555-65.
6. Saposnik G, Barinagarrementeria F, Brown Jr RD, Bushnell CD, Cucchiara B, Cushman M, December G, Ferro JM, Tsai FY. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011 Apr;42(4):1158-92.
7. Ameri A, Bousser MG. Cerebral venous thrombosis. Neurologic clinics. 1992 Feb 1;10(1):87-111.
8. Putaala J, Hiltunen S, Salonen O, Kaste M, Tatlisumak T. Recanalization and its correlation to outcome after cerebral venous thrombosis. Journal of the neurological sciences. 2010 May 15;292(1-2):11-5.
9. Vaphiades MS, Cure J. Diagnostic Techniques in Neurovascular Disorders. International ophthalmology clinics. 2009 Jul 1;49(3):103-18.
10. Buyck PJ, Zuurbier SM, Garcia-Esperon C, Barboza MA, Costa P, Escudero I, Renard D, Lemmens R, Hinteregger N, Fazekas F, Conde JJ. Diagnostic accuracy of non-contrast CT imaging markers in cerebral venous thrombosis. Neurology. 2019 Feb 19;92(8):e841-51.
11. Chen SP, Fuh JL, Wang SJ. Reversible cerebral vasoconstriction syndrome: current and future perspectives. Expert review of neurotherapeutics. 2011 Sep 1;11(9):1265-76.
12. Miranda B, Ferro JM, Canhao P, Stam J, Bousser MG, Barinagarrementeria F, Scoditti U, ISCVT Investigators. Venous thromboembolic events after cerebral vein thrombosis. Stroke. 2010 Sep 1;41(9):1901-6.
13. Patel SI, Obeid H, Matti L, Ramakrishna H, Shamoun FE. Cerebral venous thrombosis: current and newer anticoagulant treatment options. The neurologist. 2015 Nov 1;20(5):80-8.
14. Tadi P, Behgam B, Baruffi S. Cerebral venous thrombosis.
15. Lai CC, Ko WC, Chen CJ, Chen PY, Huang YC, Lee PI, Hsueh PR. COVID-19 vaccines and thrombosis with thrombocytopenia syndrome. Expert Review of Vaccines. 2021 Aug 3;20(8):1027-35.
16. Fajardo R, García N, Díaz F. Transperitoneal laparoscopic adrenalectomy for the resection of large size pheochromocytoma: Case report and literature review. International Journal of Surgery Case Reports. 2020 Jan 1;71:353-9.
17. Abdalkader M, Shaikh SP, Siegler JE, Cervantes-Arslanian AM, Tiu C, Radu RA, Tiu VE, Jillella DV, Mansour OY, Vera V, Chamorro Á. Cerebral venous sinus thrombosis in COVID-19 patients: a multicenter study and review of the literature. Journal of Stroke and Cerebrovascular Diseases. 2021 Mar 4:105733.
18. Lashkari A, Ranjbar R. A case-based systematic review on the SARS-COVID-2-associated cerebrovascular diseases and the possible virus routes of entry. Journal of Neurovirology. 2021 Sep 21:1-1.
19. Duplaga BA, Rivers CW, Nutescu E. Dosing and monitoring of low-molecular-weight heparins in special populations. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2001 Feb;21(2):218-34.
20. Kaur P, Bhat S, Sharma S, Gupta A. Early Anticoagulation Post LSCS in a Symptomatic Cortical Venous Thrombosis with Protein-S Deficiency. JK Science. 2013 Jul 1;15(3):148.
21. Khan, K., Chaturvedi, A., 2020. Rare Presentation and Successful Management of Cerebral Sinus Venous Thrombosis in a Patient with Sickle Cell Trait. JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH 14, OD09-OD10. https://doi.org/10.7860/JCDR/2020/44722.13842
22. Thool, A., Bajpayee, N., Ramani, R.L., 2020. Pulsatile Proptosis, Secondary to Carotid Cavernous Sinus Fistula-A Case Report. JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH 14, ND03–ND05. https://doi.org/10.7860/JCDR/2020/46013.14324
23. Nayak, A., Acharya, S., Ghule, A., 2020. Bilateral Orbital Cellulitis with Pan Sinusitis in a Female. JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS 9, 1464–1466. https://doi.org/10.14260/jemds/2020/319
24. Daigavane, Sachin, Madhumita Prasad, Sana Beg, and Jigna Motwani. "Invasive Aspergillosis of Right Maxillary Sinus with Orbital Extension in an Immunocompetent Individual." JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2021. https://doi.org/10.7860/JCDR/2021/47244.14718.
25. Ghungrud, Deepali, Ranjana Sharma, Seema Singh, and RuchiraAnkar. "A Rare Case of Pansinusitis Fungal Mucormycosis with Orbital Involvement in Post COVID-19 Patient and Its Treatment." Journal of Pharmaceutical Research International, September 21, 2021, 114–18. https://doi.org/10.9734/jpri/2021/v33i44B32656.

DOI: 10.9756/INTJECSE/V14I4.316